Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 321-328

  Antachopoulos, Charalampos ^a   Meletiadis, Joseph ^a   Sein, Tin ^a   Roilides, Emmanuel ^a,b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(2 METHOXY 4 NITRO 5 SULFOPHENYL) 2H TETRAZOLIUM 5 CARBOXANILIDE; ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BROTH DILUTION; CONIDIUM; FUNGAL SPORE GERMINATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; SPORES, FUNGAL;

EID: 37849008993     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00699-07     Document Type: Article

References (33)

1. Antachopoulos, C., J. Meletiadis, T. Sein, E. Roilides, and T. J. Walsh. 2007. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob. Agents Chemother. 51:881-887.
2. Antachopoulos, C., J. Meletiadis, T. Sein, E. Roilides, and T. J. Walsh. 2007. Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J. Antimicrob. Chemother. 59:230-237.
3. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.
4. Bowman, J. C., G. K. Abruzzo, A. M. Flattery, C. J. Gill, E. J. Hickey, M. J. Hsu, J. Nielsen Kahn, P. A. Liberator, A. S. Misura, B. A. Pelak, T. C. Wang, and C. M. Douglas. 2006. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob. Agents Chemother. 50:4202-4205.
5. Brummer, E., S. D. Chauhan, and D. A. Stevens. 1999. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J. Antimicrob. Chemother. 43:491-496.
6. Cacciapuoti, A., J. Halpern, C. Mendrick, C. Norris, R. Patel, and D. Loebenberg. 2006. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother. 50:2587-2590.
7. Chamilos, G., R. E. Lewis, N. Albert, and D. P. Kontoyiannis. 2007. The paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
8. Chiller, T., K. Farrokhshad, E. Brummer, and D. A. Stevens. 2001. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 39:99-103.
9. Choi, J. H., E. Brummer, and D. A. Stevens. 2004. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect. 6:383-389.
10. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
11. Denning, D. W., K. A. Marr, W. M. Lau, D. P. Facklam, V. Ratanatharathorn, C. Becker, A. J. Ullmann, N. L. Seibel, P. M. Flynn, J. A. van Burik, D. N. Buell, and T. F. Patterson. 2006. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53:337-349.
12. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
13. Espinel-Ingroff, A. 2003. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41:403-409.
14. Gardiner, R. E., P. Souteropoulos, S. Park, and D. S. Perlin. 2005. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 43(Suppl. 1):S299-S305.
15. Heyn, K., A. Tredup, S. Salvenmoser, and F. M. Muller. 2005. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob. Agents Chemother. 49:5157-5159.
16. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
17. Lewis, R. E., and D. P. Kontoyiannis. 2005. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J. Antimicrob. Chemother. 56:887-892.
18. Liu, J., and M. K. Balasubramanian. 2001. 1,3-beta-Glucan synthase: a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 1:159-169.
19. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
20. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5- [(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
21. Motulsky, H. J., and A. Christopoulos. 2003. Complex dose-response curves, p. 290-295. In H. J. Motulsky and A. Christopoulos (ed.), Fitting models to biological data using linear and nonlinear regression. GraphPad Software Inc., San Diego, CA.
22. Motulsky, H., J., and A. Christopoulos. 2003. Introduction to dose-response curves, p. 256-265. In H. J. Motulsky and A. Christopoulos (ed.), Fitting models to biological data using linear and nonlinear regression. GraphPad Software Inc., San Diego, CA.
23. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. NCCLS, Wayne, PA.
24. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
25. Paderu, P., G. Garcia-Effron, S. Balashov, G. Delmas, S. Park, and D. S. Perlin. 2007. Serum differentially alters the antifungal properties of echino-candin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
26. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
27. Rodriguez-Tudela, J. L., E. Chryssanthou, E. Petrikkou, J. Mosquera, D. W. Denning, and M. Cuenca-Estrella. 2003. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J. Clin. Microbiol. 41:5236-5237.
28. Serrano Mdel, C., A. Valverde-Conde, M. M. Chavez, S. Bernal, R. M. Claro, J. Peman, M. Ramirez, and E. Martin-Mazuelos. 2003. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. Diagn. Microbiol. Infect. Dis. 45:131-135.
29. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
30. Stevens, D. A., M., Ichinomiya, Y., Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
31. Wagner, C. W. Graninger, E. Presterl, and C. Joukhadar. 2006. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78:161-177.
32. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.
33. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs 12:1313-1333.